Entrapment of anti-DNA antibodies in the kidney of patients with systemic lupus erythematosus. Antibodies to single-stranded DNA (antissDNA) and double-stranded DNA (anti-dsDNA) were determined in serum and urine of nine patients with systemic lupus erythematosus (SLE) presenting with heavy proteinuria (>300 mg/dl), and the activity of anti-DNA antibodies was compared between paired serum and urine samples in each patient. The results were expressed by the anti-DNA activity (radioimmunoassay units per milliliter) divided by the concen-
. L'impossibilité de détecter les anti-DNA dans l'urine des malades avec an SLE n'était cependant pas due au ssDNA contenu dans l'urine, puisqu'aucune activité anti-DNA n'a ete ddtectée, méme après que les échantillons urinaires aient été digeres avec de la desoxyribonuclease. Sur Ia base de ces résultats, les anti-DNA du serum des malades ayant un SLE ant été considérés séquestres dans le rein, probablement en raison de leur liaison au DNA depose dans leurs glomérules.
also as an indicator of the disease activity. Levels of anti-DNA antibodies have been reported to correlate with clinical activity and also with renal involvement 11-71. However, there are patients in whom the anti-DNA titer may start to decrease as they develop heavy proteinuria and the nephrotic syndrome 181.
Indeed, anti-DNA antibodies in these patients sometimes de- crease to a level too low to be detected by the fluorescent antibody technique. A possible explanation would be that anti-DNA antibodies are excreted into the urine to lower the serum level of anti-DNA antibodies. This view, however, does not conform to the presence of IgG, albeit at low concentrations, in the serum of nephrotic patients whose anti-DNA activity became undetectable. Anti-DNA antibodies have to be deprived specifically from the circulation.
Since the kidney is affected preferentially in SLE patients, possibly by a DNA-anti-DNA immune complex mechanism, it would be responsible, at least partly, for the decreased levels of anti-DNA in their sera. In this investigation, we determined the ratio of anti-DNA antibody titer to the IgG content in the urine, and compared it with that in the corresponding serum of nine patients with massive proteinuria to see if anti-DNA in the serum would be absorbed by the kidney during glomerular filtration.
Methods
Patients. Of 50 patients (3 male, 47 female, aged 21 to 53 years) who had SLE and had been attending the outpatient clinic of the Third Department of Internal Medicine of Tokyo University Hospital, 17 presented with abnormal proteinuria. Thirteen of the 17 patients had persistent proteinuria exceeding 300 mg/dl. Serum and urine samples were available in adequate quantity and condition for examination from only nine of them (Table 1 ). All 9 patients had received renal biopsy; eight were diagnosed as having membranous glomerulonephritis and the remaining one was said to have diffuse proliferative glomerulonephritis. All of them were on 5 to 20 mg of prednisolone daily at the time of the study. Urine samples were collected on the same day when blood samples were drawn. Immediately after Antibodies to double-stranded DNA (anti-dsDNA) and single-stranded DNA (anti-s5DNA) are almost always present in the serum of patients with systemic lupus erythematosus (SLE) and have been applied as a useful marker for the diagnosis and . Paired serum and urine samples were stored at -20° C until used. On the day of assay, they were thawed and heated at 56° C for 30 mm. Radio/abe/ed DNA reagents. ss-DNA was labeled with 1251 alter the method originally described by Commerford [9] . Calf thymus DNA (type 1, Sigma Chemical Co., St. Louis, Missouri) was dissolved in physiological saline at 500 tg/ml and denatured by heating at 100° C for 10 mm followed by immediate cooling in an ice bath. Mixture of 0.1 ml ssDNA solution (500 g/ml), 0.1 ml 1.25 X i04 M KI, 0.5 mCi Na'251 (New England Nuclear, Boston, Massachusetts) and 0.1 ml 7.5 >< 10 ' thallium chloride (Soekawa Chemicals, Tokyo, Japan) was heated at 60° C for 60 mm. After being cooled in an ice bath, the reaction mixture was applied to a column of Sephadex G-50 (Pharmacia Fine Chemicals, Uppsala, Sweden) equilibrated with Tris buffer for the separation of bound from free iodine.
When void volume fractions were collected and subjected to gel filtration in Bio-Gel A-l.5 m (Bio Rad Laboratories, Richmond, California), a high peak of radioactivity appeared at breakthrough fractions, but some radioactivity was detected also in retarded fractions. Only void volume fractions were collected and used as 1251-ssDNA (specific activity 2,4 tCi/g). After the gel filtration on Bio-Gel A-l.5 m, the total binding of 125j ssDNA with an excess amount of anti-DNA increased from 73 to 91%.
'25IdsDNA was obtained from a commercial source (Amersham, Buckingham shire, England).
Anti-DNA antibodies. Five microliters of serum or concentrated urine sample were diluted with Tris buffer to 50 J and mixed with 10 .d of Tris buffer containing 2 ng of '251-ssDNA (or 25 .d of 1251-dsDNA solution) in a glass tube measuring 12 x 75 mm. Tubes were incubated for 1 hr at 37° C and for 18 hr at 4° C. Then, 50 d of rabbit antiserum containing anti-human IgG antibodies were added. After 30 mm of incubation at room temperature, the formed precipitate was washed twice by centrifuging xl,000g for 10 mm. The radioactivity in the precipitate was counted by a gammacounter. The results were expressed as the number of radioimmunoassay (RIA) units contained in 1 ml of the sample. One RIA unit was defined as the amount of anti-DNA which could bind with 50% of the added radioactivity. Usually, two or more points of twofold dilutions of the sample were assayed so as to contain 50% binding between two points.
Radioimmunoassay of human IgG. The concentration of IgG in serum and urine was determined by radioimmunoassay. Human IgG (HGG, Miles Laboratories Inc., Elkhart, Indiana)
was labeled with 125j b chloramin T method [101 and '251-HGG with a specific activity of 2.5 Ci/rg was obtained. Serum and concentrated urine samples were diluted appropriately with Tris buffer and a portion (5 to SO l) was delivered to a glass tube. The total volume was adjusted to 50 /Ll with the buffer. Ten microliters of Tris buffer containing 0.005 d rabbit antihuman IgG/y antiserum (Sigma Chemical Co., St. Louis, Missouri) and 1 d of normal rabbit serum were delivered to each tube, and after a disequilibrium time of 2 hr at 24° C, 10 ng of '25IHGG in 10 tl of Tris buffer were added. After a further incubation for 2 hr at 24° C and 18 hr at 4° C, 15 l of goat antirabbit IgG antiserum were added. Tubes were allowed to stand for 30 mm at 24° C. The formed precipitate was washed twice and the radioactivity was counted. Using serial dilution of the standard HGG, an inhibition curve was drawn. igG concentration in the test sample was determined by comparing its inhibition with the standard inhibition curve.
Radioimmunoassay of ssDNA. Radioimmunoassay of ssDNA was performed using anti-ssDNA antibody raised in rabbits. Five-hundred micrograms of denatured calf thymus DNA (type 1) dissolved in 1 ml of saline were complexed to 50 l of 1% methylated bovine serum albumin (Sigma Chemical
Co., St. Louis, Missouri), and emulsified in the same volume of
Freund's complete adjuvant (Difco Laboratories, Detroit, Michigan). Each rabbit received 2.0 ml of the emulsion in hind footpads and intracutaneously four times at a week interval. One week after the last injection, blood was drawn and the serum was separated.
Urine samples were diluted with Tris buffer to the final volume of 50 1 in a glass tube and incubated with 10 1 of Tris buffer containing 0.005 l of rabbit anti-DNA antiserum and 1 .d of normal rabbit serum at 24° C for 2 hr. Then 4 ng of 125j ssDNA in 10 pJ of Tris buffer were added to each tube. After an incubation for 2 hr at 24° C and then for 18 hr at 4° C, 15 /Ll of goat anti-rabbit IgG antiserum (Miles Laboratories Inc., Elkhart, indiana) were added. Tubes were allowed to stand for 30 mm at 24° C. The formed precipitate was washed twice by centrifuging at xl,000g for 10 mm, and the radioactivity was counted. Using a serial dilution of ssDNA, the standard curve was drawn. ssDNA in the test sample was determined by comparing its inhibition with the standard curve. Deoxyribonuclease digestion. Digestion of DNA by deoxyribonuclease (DNase) was carried out with a slight modification of the method originally described by Harbeck et al [11] . Fortyfive microliters of serum or concentrated urine sample were mixed with 5 tg of DNase I (Sigma Chemical Co., St. Louis, Missouri) dissolved inS tl of phosphate buffer (0.02 M, pH 7.4) containing 0.13 M NaCI (phosphate-buffered saline, PBS) in the presence of 0.15 mole MgCl2. In the control (undigested) sample, DNase was substituted by PBS. Samples were incubated at 37° C for 1 hr followed by an overnight incubation at 4° C and then 2 hr at 24° C. Five microliters of 0.5 M tetrasodium ethylene diamine tetraaceteic acid (EDTA) dissolved in distilled water were added to samples to stop the digestion. To achieve a final serum dilution of 1:10, 395 t1 of borate buffer (0.01 M, pH 8.3) were added to the sample. To the undigested control, 395 d of borate buffer containing 5 g of DNase I and 0.15 prnole of MgCl2 were added. A 200-pd portion was taken from each sample and the activity to bind with DNA was determined by radioimmunoassay.
Determination of anti-nuclear factors. Determination of antinuclear factors (AN F) was carried out according to the method described by Beck [12] . The pattern of a representative serum (patient no. 6) is g illustrated in Figure 1 . Anti-DNA activity was detected almost exclusively in fractions containing IgG. The other serum con-! centrations showed similar patterns of anti-DNA activity.
3.0
Based on these results, following anti-DNA assays were per-< formed by the double antibody method using rabbit antiserum to human IgG as a second antibody.
1.0
Comparison of anti-DNA activity in the serum and urine samples of patients with proteinuria. Anti-DNA was determined in the nine patients with proteinuria (>300 mg/dl) listed in Table 1 . Anti-DNA activity in the urine was compared with that in the serum by means of the following index.
Anti-DNA activity (RIA U/mi) IgG content (mg/mi)
The results are summarized in Table 2 . All of these serum concentrations were positive for anti-ssDNA (range, 42 to 450, mean 219 RIA U/ml), as well as for anti-dsDNA (range, 58 to 1,250, mean 251 RIA U/mi). Anti-ssDNA and -dsDNA activities
were not detectable in concentrated urine samples from all these patients (less than 1). Consequently, the indices of urine samples were extremely low (less than 1.0) contrasting with those of the corresponding serum samples which measured 4.8 to 27.2 for anti-ssDNA and 5.6 to 107.8 for anti-dsDNA. These results indicated that although IgG molecules (which accounted for the majority of anti-DNA activity in the serum, see above) were excreted in substantial amounts into the urine of these patients, the amount of anti-DNA in the urine was very little. ANF in various patterns was detected in serum and concentrated urine in some of the patients with a titer roughly in parallel with the concentration of IgG.
The low indices of SLE patients were not due to the overestimation of urinary IgG by small degradates of IgG bearing its antigenicity but devoid of antibody activity, such as Fc and Fe' fragments. Figure 2 shows the profile of IgG activity in the urine fractionated through a Sephacryl S-200 column. Essentially all the IgG detectable by radioimmunoassay appeared at the position of intact IgG molecules, thereby indicating that the contribution of fragments of IgG to the assay would be little, if any. Excretion of DNA into the urine of SLE patients. Although the ratio of anti-DNA antibody titer to the IgG content in the urine of SLE patients with proteinuria was found to be much lower than that in the corresponding serum, anti-DNA in the glomerular filtrate, if present, could have been consumed during its passage through the urinary tract. To evaluate this possibility, we tested for the presence of ssDNA in the urine of SLE patients and normal controls.
When urine samples of patients were concentrated and tested by radioimmunoassay, all of them were found to contain ssDNA. Figure 3 shows the inhibition curve of urine from a representative patient.
The amount of ssDNA excreted was standardized on the basis of creatinine to correct for the concentration of urine.
ssDNA (ig)/creatinine (mg) in the urine from 28 SLE patients er. A 50-pi portion of each fraction was tested for anti-ssDNA by radioimmunoassay, in which (NH4)2S04 was used for precipitating radioactive DNA bound with antibodies of all classes [13] . 
<1.0
One RIA unit is the amount of antibody required to induce 50% binding with the radiolabeled antigens. b Urine samples were concentrated 50-to 100-fold. "Anti-nuclear factors were determined by indirect immunofluorescent technique using rat liver sections. The titer was expressed as the highest dilution which induced detectable nuclear fluorescence with homogeneous (h), speckled (s), and peripheral (p) patterns.
d NT, not tested. To see if DNA in the urine of SLE patients had been complexed with anti-DNA and would give negative results in anti-ssDNA assays even though it had been existent, the following experiment was carried out (Table 3) . Serum and concentrated urine samples from the nine patients were tested for binding with '251-ssDNA before and after DNase digestion. Serum samples were diluted so as to maintain the same IgG concentration as the corresponding urine samples to facilitate the comparison. At the concentration of IgG tested, anti-DNA activity was still detectable in seven serum concentrations, but it was not detectable in any of the nine urine samples. In some serum concentrations, anti-ssDNA activity increased after DNase digestion, indicating the presence of immune complexes involving ssDNA. In all the urine samples tested, however, anti-ssDNA activity was not generated even after DNase digestion, thereby indicating the absence of anti-DNA complexing with naturally occurring DNA in the urine. These results were consistent with the notion that anti-DNA had not been excreted into the urine of the patients with heavy proteinuria.
To evaluate the validity of DNase digestion, several serum 
<10
a Forty-five milliliters of serum or urine sample were incubated with 5 g of DNase for 1 hr at 37° C and an additional 18 hr at 4° C and 2 hr at 24°C. Then 5 1.d of 0.5 M EDTA and 395 1 of borate buffer were added to stop the digestion. A 200-pd portion was tested for the binding with 2 ng ssDNA by radioimmunoassay. In the undigested control samples, EDTA was added prior to the treatment with DNase.
b Serum samples were diluted to maintain the same IgG concentration as in the corresponding urine samples.
'One RIA unit is the amount of antibody required to induce 50% binding with the radiolabeled antigens.
samples from SLE patients containing anti-ssDNA were incubated with an excess amount of ssDNA for 1 hr at 37°C and an additional 18 hr at 4°C. After the digestion of the mixture with DNase, anti-DNA activity was determined and compared with that of the untreated serum. Anti-DNA activity of 70% or more of the original serum was invariably recovered after digesting ssDNA-anti-ssDNA complexes.
Discussion
Hecht et al [81 noted a rapid decrease in DNA binding activity of the serum from SLE patients with massive proteinuria. We also observed that the serum levels of anti-DNA in some SLE patients decreased after they developed nephrotic syndrome (unpublished observations). To evaluate the contribution of urinary loss of anti-DNA to the lowered level of circulating anti-DNA in nephrotic patients, we determined anti-DNA activity and IgG concentration in paired serum and urine samples of nine patients with heavy proteinuria. In all of these patients, anti-DNA activity was barely detectable in the urine which had been concentrated 50-to 100-fold, and accordingly, the ratio of anti-DNA activity (RIA units/mi) to IgG concentration (mg/ml) was much lower for the urine than for the corresponding serum. This led us to suspect a specific deprivation of anti-DNA from IgG in the process of urine formation. The standardization of anti-DNA activity to IgG was based on the finding that IgG substantiated essentially all of the anti-DNA activity in the serum concentrations of SLE patients on the present series, in accordance with the reports of others [14] [15] [16] .
The failure to detect anti-DNA in the urine was not due to substances which inhibited antigen-antibody reactions, since both IgG and ANF were detectable in the urine by immunological methods without any difficulties. When urine samples were fractionated by gel filtration, essentially all the antigenic activity of IgG appeared at the position of intact IgG molecules. Therefore, the low ratio of anti-DNA/IgG in the urine of SLE patients was not due to the overestimation of IgG by detecting fragments of IgG without antibody activity.
An incidental finding was the presence of ssDNA in the urine of SLE patients, as well as in that of normal individuals, although its origin was not identified in this study. ssDNA would be too large to be filtered across the glomerular basement membrane (GBM) into the urine. A contamination from cellular elements in the urine was avoided, as far as possible, by the centrifugation immediately after voiding. Therefore, ssDNA would have been added to the urine while it passed through the urinary tract; it might have been released from tubular cells as a product of their metabolism. dsDNA molecules might have been present in the urine also, but it was not determined owing to the difficulty in obtaining anti-dsDNA of the defined specificity.
The presence of ssDNA in the urine of SLE patients left us with the possibility that anti-ssDNA might have been excreted into the urine but escaped the detection due to their binding with ssDNA contained in the urine. This was not the case, however, because no anti-DNA activity was generated in the urine even after it had been digested with DNase, a procedure capable of liberating anti-DNA antibodies from immune complexes involving DNA antigens [11] . Furthermore, Sarai et al [171 reported that anti-DNA complexed with DNA antigens was detected more easily when it had been incubated with excess antigens prior to the digestion with DNase. Their view was substantiated by our finding that sera containing anti-ssDNA, when incubated with an excess amount of ssDNA and then digested with DNase, recovered at least 70% of the original anti-ssDNA activity. These lines of evidence precluded the presence of anti-ssDNA antibodies in the urine of these patients; anti-DNA in urine samples, even if it had been complexed with DNA antigens, would not have escaped the detection. Accordingly, we had to postulate the entrapment of anti-DNA antibodies by the kidney during their passage through renal glomeruli. Since the other anti-nuclear antibodies, in homogenous and speckled patterns, were detectable by immunofluorescent method in the concentrated urine of the patients, anti-DNA antibodies would have been specifically taken up by the kidneys of SLE patients.
Among many organs involved in SLE, the kidney is affected most frequently. It is known to be involved even in the very early stage of the disease [18] , and DNA-anti-DNA complexes have been implicated in the pathogenesis of lupus nephritis [19] . There have been several reports which documented anti-DNA antibodies in the affected kidney of SLE patients; anti-DNA antibodies were demonstrated in a high concentration in acid buffer or DNase eluate of nephritic kidneys [20] [21] [22] [23] . The eluted anti-DNA antibodies appeared to have been complexed with DNA antigens deposited in the kidney; the antigens were stained by fluoresceinated anti-DNA reagents after the elution of anti-DNA [23, 24] . It is not clear, however, how DNA-anti-DNA complexes were localized in the kidney. Some investigators claim that circulating DNA-anti-DNA complexes may be deposited in renal glomeruli during their passage through the kidney [11, 25, 26] . However, circulating immune complexes are not always demonstrable in the serum of patients with lupus nephritis even with the advent of various methods.
Izui, Lambert, and Miescher [27] proposed a hypothesis that DNA-anti-DNA complexes would be formed in situ in renal glomeruli, on the basis of their finding that DNA molecules showed an affinity to GBM. DNA molecules, once attached to GBM, would be able to bind with circulating anti-DNA. Our data appear to support their hypothesis. Indeed, during its filtration through GBM, anti-DNA antibodies in the serum of our patients may have been entrapped by renal glomeruli to which DNA antigens had been already fixed by non-immunological processes, so that we could not find anti-DNA activity in their urine. The entrapment of anti-DNA antibodies by renal glomeruli reported herein by no means rules out the contribution of circulating immune complexes to the lowered level of anti-DNA in the serum of nephritic patients. When DNA antigens are released into the circulation of SLE patients by unidentified mechanism, they would bind with anti-DNA, form immune complexes, and then be cleared away by the reticuloendothelial system. A part of such immune complexes would deposit in renal glomeruli. Some antigenic sites of DNA might still be available on the surface of DNA-anti-DNA complexes deposited in the kidney, which, in turn, could bind with circulating anti-DNA antibodies to form complexes in situ. Indeed, these processes operating in concert would be responsible for the lowered anti-DNA levels in the serum concentrations of SLE patients with renal involvement.
